Irritability · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
1 finding from 1 review
Aggression · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
Antidepressants may leads to higher adverse effects compared with placebo (low certainty).
1 finding from 1 review
Aggression · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
1 finding from 1 review
Self‐injury · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
1 finding from 1 review
Adverse effects (AEs) · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
Atypical antipsychotics may leads to higher adverse effects (AEs) compared with placebo (low certainty).
1 finding from 1 review
Irritability · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
1 finding from 1 review
Sustained adherence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adherence to iron chelation therapy (%, SD)
1 finding from 1 review
SAEs ‐ thalassaemia‐related SAEs
It is very uncertain whether summary of findings: Comparison 2 ‐ deferasirox (DFX) changes SAEs Thalassaemia‐related SAEs compared with deferiprone (DFO) (very low certainty).
1 finding from 1 review
SAEs ‐ SCD‐related SAEs
1 finding from 1 review
All‐cause mortality
1 finding from 1 review
Disease-free survival · Adults with oropharyngeal cancer
Surgery showed no clear difference in disease-free survival (new disease, progression, and mortality) compared with radiotherapy alone (low certainty).
1 finding from 1 review
Recurrence · Adults with oropharyngeal cancer
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events associated with treatment · Adults with oral cavity or oropharyngeal cancer
1 finding from 1 review
Adverse events: severe acute effects in both groups (subcutaneous fibrosis, telangiectasia, moderate-to-severe oedema, xerostomia, trismus, dysphagia); subcutaneous fibrosis more prevalent with surgery + radiotherapy…
1 study · 35 participants
Very low
Adverse events: thromboses · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes adverse events: thromboses compared with oral steroids alone (very low certainty).
1 finding from 1 review
Gastrointestinal bleeding · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes adverse events: gastrointestinal bleeding compared with oral steroids alone (very low certainty).
1 finding from 1 review
Complete remission · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in complete remission Time frame: 2 to 6 months compared with oral steroids alone (moderate certainty).
1 finding from 1 review
Complete or partial remission · minimal change disease in adults with nephrotic syndrome
Calcineurin inhibitors ± oral steroids showed no clear difference in complete or partial remission time frame: 3 to 6 months compared with oral steroids alone (moderate certainty).
1 finding from 1 review